Antineo accompanies clients in the preclinical development of novel anticancer agents. We provide strategic advice for preclinical development (choice of indications to focus on etc.), and expertise and in vitro, ex vivo and in vivo services aiming at characterising the mode of action and the anti-tumoral efficacy of new drugs.
We have a strong expertise in immunotherapies, and in the development and characterisation of original models for secondary resistances to gold standards.